Sativex regulatory approval in Switzerland

A cannabis derived drug which has been approved in some countries to treat muscle spasticity.

Sativex regulatory approval in Switzerland

Postby MSUK » Wed Nov 27, 2013 1:52 am

GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has received regulatory approval for its prescription medicine Sativex(R) in Switzerland. A full marketing authorization has been granted by the Swissmedic authorities in the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications. Launch timing is dependent on completion of pricing and reimbursement procedures. Sativex will be commercialized in Switzerland by GW's European partner, Almirall S.A......Read More - http://www.ms-uk.org/sativex
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 1985
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Sativex

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users